Therapeutic drug monitoring (TDM) and population pharmacokinetics (PPK)

详细信息	查看全文 | 推荐本文 |

• 作者：Bengtsson ; F. ; Hö ; glund ; P. ; Liden ; A. ; Nordin ; C. ; Walinder ; J.
• 刊名：European Psychiatry
• 出版年：1997
• 期刊代码：96_09249338
• 类别：med
• 出版时间：1997
• 卷：12
• 期：Supplement 2
• 页码：171s
• 文件大小：86.8 K

摘要

Thymoleptic SSRIs F=fluvoxamine (introduced in Sweden in June 1990), P=paroxetine (June 1991) and C=citalopram (+ desmethylcit.; Oct. 1992) were subjected to postmarketing surveillance by introducing serum RP-HPLC (UV-detect.) analytical methods determining the F (from Oct. 1992), P (Nov. 1992), and C (April 1993) for routine use in southern Sweden (pop. 3 mill). Specifically designed TDM-request forms were used to acquire adequate clinical data. Stratification of the data made us perform traditional statistics as well as PPK modelling on this large and naturalistic clinical phase-IV cohort. By June 1994 the collection of such data amounted to 363 (F), 775 (P) and 778 (C) TDM-analyses. Eligible data were subjected to NONMEMR PPK-calculations and as an example the paroxetine estimates from two time points (Oct. 1993; 129 TDM-analyses/115 patients and June 1994; 333 TDM-analyses/268 patients) displayed: elim t to be dependent on sex and co-medication; t = males 28 h vs. females 36 h. Vd was dependent on sex; males 281 L vs. females 406 L. Oral clearance (Clo) was dependent on sex, age and co-medication: